Necrotizing fasciitis: Pathogenesis and treatment

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 2, 2005, Pages 279-294

  Young, Michael H ^a   Aronoff, David M ^b   Engleberg, N Cary ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antimicrobial therapy; Bacterial; Bacterial toxins; Clindamycin; Fasciitis; Necrotizing; Penicillins; Risk factors; Septic shock; Skin diseases; Streptococcus pyogenes; Superantigens

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; CORTICOSTEROID; DAPTOMYCIN; DROTRECOGIN; HYALURONIC ACID; IMMUNOGLOBULIN; LINEZOLID; M PROTEIN; METICILLIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OPSONIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PEPTIDASE; PIPERACILLIN PLUS TAZOBACTAM; STREPTOCOCCUS VACCINE; SULTAMICILLIN; TIMENTIN; VANCOMYCIN; VIRULENCE FACTOR;

AGE; ALCOHOL ABUSE; ALCOHOLISM; ANALGESIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BACTERIUM ISOLATION; CARCINOMA; CHEMOTAXIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEBRIDEMENT; DIABETES MELLITUS; DISEASE COURSE; DOWN REGULATION; DRUG ABUSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ESCHERICHIA COLI; HEART DISEASE; HEART FAILURE; HEMODYNAMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBARIC OXYGEN; HYPERBARISM; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RATE; INFECTION RISK; KIDNEY FAILURE; MALNUTRITION; MORBIDITY; MORTALITY; NECROTIZING FASCIITIS; NEUTROPHIL; NONHUMAN; OBESITY; OPSONIZATION; PATHOGENESIS; PATIENT CARE; PHAGOCYTOSIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STREPTOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; DEBRIDEMENT; FASCIITIS, NECROTIZING; HUMANS; INCIDENCE; RISK FACTORS; STREPTOCOCCUS PYOGENES; UNITED STATES;

EID: 17844369698     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.2.279     Document Type: Review

References (143)

1. Eke N. Fournier's gangrene: a review of 1726 cases. Br. J. Surg. 87(6), 718-728 (2000).
2. Descamps V, Aitken J, Lee MG. Hippocrates on necrotising fascilitis. Lancet 344(8921), 556 (1994).
3. Dellinger EP. Severe necrotizing soft-tissue infections. Multiple disease entities requiring a common approach. J. Am. Med. Assoc. 246(15), 1717-1721 (1981).
4. Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest 110(1), 219-229 (1996).
5. Loudon I. Necrotising fasciitis, hospital gangrene, and phagedena. Lancet 344(8934), 1416-1419 (1994).
6. Meleney F. Hemolytic streptococcal gangrene. Arch. Surg. 9, 317-614 (1924).
7. Wilson B. Necrotizing fasciitis. Am. Surg. 18(4), 416-431 (1952).
8. Giuliano A, Lewis F, Hadley K et al. Bacteriology of necrotizing fasciitis. Am. J. Surg. 134(1), 52-57 (1977).
9. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg. Infect. Dis. 1(3), 69-78 (1995).
10. Brown A. Flesh-Eating Killer Has Doctors Baffled. Press Association Ltd, London, UK (1994).
11. O'Brien KL. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin. Infect. Dis. 35(3), 268-276 (2002).
12. Childers BJ, Potyondy LD, Nachreiner R et al. Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am. Surg. 68(2), 109-116 (2002).
13. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann. Surg. 224(5), 672-683 (1996).
14. Wong CH, Chang HC, Pasupathy S et al. Necrotizing fasciitis: clinical presentation, microbiology and determinants of mortality. J. Bone Joint Surg. Am. 85A(8), 1454-1460 (2003).
15. Andreasen TJ, Green SD, Childers BJ. Massive infectious soft-tissue injury: diagnosis and management of necrotizing fasciitis and Purpura fulminans. Plast. Reconstr. Surg. 107(4), 1025-1035 (2001).
16. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin. Infect. Dis. 33(Suppl. 2) S84-S93 (2001).
17. Kaul R, McGeer A, Low DE et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am. J. Med. 103(1), 18-24 (1997).
18. Sharkawy A, Low DE, Saginur R et al. Severe group a streptococcal soft-tissue infections in Ontario: 1992-1996. Clin. Infect. Dis. 34(4), 454-460 (2002).
19. Stevens DL. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Ann. Rev. Med. 51, 271-288 (2000).
20. Stevens DL. Invasive group A streptococcus infections. Clin. Infect. Dis. 14(1), 2-11 (1992).
21. Simonart T, Simonart JM, Derdelinckx I et al. Value of standard laboratory tests for the early recognition of Group A β-hemolytic streptococcal necrotizing fasciitis. Clin. Infect. Dis. 32(1), E9-E12 (2001).
22. Stevens DL, Tanner MH, Winship J et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321(1), 1-7 (1989).
23. Factor SH. Invasive group A streptococcal disease: risk factors for adults. Emerg. Infect. Dis. 9(8), 970-977 (2003).
24. Brun-Buisson CJ, Saada M, Trunet P et al. Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs. Br. Med. J. (Clin. Res. Ed.) 290(6484), 1786 (1985).
25. Zerr DM, Rubens CE. NSAIDS and necrotizing fasciitis. Pediatr. Infect. Dis. J. 18(8), 724-725 (1999).
26. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal anti-inflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine 82(4), 225-235 (2003).
27. Dahl PR, Perniciaro C, Holmkvist KA et al. Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J. Am. Acad. Dermatol. 47(4), 489-492 (2002).
28. Wong CH, Khin LW, Heng KS et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit. Care Med. 32(7), 1535-1541 (2004).
29. Hite K Locke M, Hesseltine H. Synergism in experimental infections with nonsporulating anaerobic bacteria. J. Infect. Dis. 84, 1 (1949).
30. Roberts DS. The pathogenic synergy of Fusiformis necrophorus and Corynebacterium pyogenes. Influence of the leucocidal exotoxin of F. necrephorus. Br. J. Exp. Pathol. 48(6), 665-673 (1967).
31. Roberts DS. Synergic mechanism in certain mixed infections. J. Infect. Dis. 120(6), 720-724 (1969).
32. Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect. Dis. 3(4), 191-200 (2003).
33. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13(3), 470-511 (2000).
34. Betschel SD, Borgia SM, Barg NL et al. Reduced virulence of group A streptococcal Tn916 mutants that do not produce streptolysin S. Infect. Immun. 66(4), 1671-1679 (1998).
35. Engleberg NC, Heath A, Vardaman K et al. Contribution of CsrR-regulated virulence factors to the progress and outcome of murine skin infections by Streptococcus pyogenes. Infect. Immun. 72(2), 623-628 (2004).
36. Sun H, Ringdahl U, Homeister JW et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305(5688), 1283-1286 (2004).
37. McIver KS, Scott JR. Role of Mga in growth phase regulation of virulence genes of the group A streptococcus. J. Bacteriol. 179(16), 5178-5187 (1997).
38. Graham MR, Smoot LM, Migliaccio CA et al. Virulence control in group A streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc. Natl Acad. Sci. USA 99(21), 13855-13860 (2002).
39. Levin JC, Wessels MR. Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A streptococcus. Mol. Microbiol. 30(1), 209-219 (1998).
40. Miller AA, Engleberg NC, DiRita VJ. Repression of virulence genes by phosphorylation-dependent oligomerization of CsrR at target promoters in S. pyogenes. Mol. Microbiol. 40(4), 976-990 (2001).
41. Chaussee MS, Sylva GL, Sturdevant DE et al. Rgg influences the expression of multiple regulatory loci to coregulate virulence factor expression in Streptococcus pyogenes. Infect. Immum. 70(2), 762-770 (2002).
42. Granok AB, Parsonage D, Ross RP et al. The RofA binding site in Streptococcus pyogenes is utilized in multiple transcriptional pathways. J. Bacteriol. 182(6), 1529-1540 (2000).
43. Kreikemeyer B, Boyle MD, Buttaro BA et al. Group A streptococcal growth phase-associated virulence factor regulation by a novel operon (Fas) with homologies to two-component-type regulators a small RNA molecule. Mol. Microbiol. 39(2), 392-406 (2001).
44. Podbielski A, Woischnik M, Leonard BA et al. Characterization of nra, a global negative regulator gene in group A streptococci. Mol. Microbiol. 31(4), 1051-1064 (1999).
45. Darenberg J, Ihendyane N, Sjolin J et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37(3), 333-340 (2003).
46. Chaussee MS, Liu J, Stevens DL et al.. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J. Infect. Dis. 173(4), 901-908 (1996).
47. Norrby-Teglund A, Kaul R, Low DE et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T-cell proliferation and cytokine production. J. Immunol. 156(8), 3057-3064 (1996).
48. Norrby-Teglund A, Thulin P, Gan BS et al. Evidence for superantigen involvement in severe group a streptococcal tissue infections. J. Infect. Dis. 184(7), 853-860 (2001).
49. Chatellier S, Ihendyane N, Kansal RG et al. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect. Immun. 68(6), 3523-3534 (2000).
50. Johnson DR, Wotton JT, Shet A et al. A comparison of group A streptococci from invasive and uncomplicated infections: are virulent clones responsible for serious streptococcal infections? J. Infect. Dis. 185(11), 1586-1595 (2002).
51. Kotb M, Norrby-Teglund A, McGeer A et al. Association of human leukocyte antigen with outcomes of infectious diseases: the streptococcal experience. Scand. J. Infect. Dis. 35(9), 665-669 (2003).
52. Lungstras-Bufler K, Bufler P, Abdullah R et al. High cytokine levels at admission are associated with fatal outcome in patients with necrotizing fasciitis. Eur. Cytokine Netw. 15(2), 135-138 (2004).
53. Kotb M, Norrby-Teglund A, McGeer A et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nature Med. 8(12), 1398-1404 (2002).
54. Norrby-Teglund A, Chatellier S, Low DE et al. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur. J. Immunol. 30(11), 3247-3255 (2000).
55. Henriques Normark B, Normark S. Hosting for the cruel and the inconsequential. Nature Med. 8(12), 1349-1350 (2002).
56. Norrby-Teglund A. Nepom GT, Kotb M. Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alletes. Eur. J. Immunol. 32(9), 2570-2577 (2002).
57. Basma H, Norrby-Teglund A, Guedez Y et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect. Immun. 67(4), 1871-1877 (1999).
58. Mascini E, Hazenberg M. Invasive group A streptococcal disease, association with a lack of anti-exotoxin antibodies. In: Streptococci and the Host. Horaud T, Bouvet A. Leclercq R, De Montclos H, Sicard M et al (Eds). Plenum Press, New York, USA (1997).
59. Norrby-Teglund A, Pauksens K, Holm SE et al. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J. Infect. Dis. 170(3), 585-591 (1994).
60. Bisno AL, Cockerill FR 3rd, Bermudez CT. The initial out-patient-physician encounter in group A streptococcal necrotizing fasciitis. Clin. Infect. Dis. 31(2), 607-608 (2000).
61. Haywood CT, McGeer A, Low DE. Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast. Reconstr. Surg. 103(6), 1567-1573 (1999).
62. Wall DB, Klein SR, Black S et al. A simple model to help distinguish necrotizing fasciitis from non-necrotizing soft-tissue infection. J. Am. Coll. Surg. 191(3), 227-231 (2000).
63. McHenry CR, Piotrowski JJ, Petrinic D et al. Determinants of mortality for necrotizing soft-tissue infections. Ann. Surg. 221(5), 558-563 (1995).
64. Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft-tissue infections. Am. J. Surg. 179(5), 361-366 (2000).
65. Ward RG, Walsh MS. Necrotizing fasciitis: 10 years' experience in a district general hospital. Br. J. Surg. 78(4), 488-489 (1991).
66. Schiodt M. Deep cervical infections - an uncommon but significant problem. Oral Dis. 8(4), 180-182 (2002).
67. Riseman JA, Zamboni WA, Curtis A et al. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 108(5), 847-850 (1990).
68. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N. Engl. J. Med. 310(26), 1689-1693 (1984).
69. Louie L, Simor AE, Louie M et al. Diagnosis of group A streptococcal necrotizing fasciitis by using PCR to amplify the streptococcal pyrogenic exotoxin B gene. J. Clin. Microbiol. 36(6), 1769-1771 (1998).
70. Fisher JR, Conway MJ, Takeshita RT et al. Necrotizing fasciitis. Importance of roentgenographic studies for soft-tissue gas. J. Am. Med. Assoc. 241(8), 803-806 (1979).
71. Wysoki MG, Santora TA, Shah RM et al. Necrotizing fasciitis: CT characteristics. Radiology 203(3), 859-863 (1997).
72. Brothers TE, Tagge DU, Stutley JE et al. Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity. J. Am. Coll. Surg. 187(4), 416-421 (1998).
73. Loh NN, Ch'en IY, Cheung LP et al. Deep fascial hyperintensity in soft-tissue abnormalities as revealed by T2-weighted MR imaging. Am. J. Roentgenol. 168(5), 1301-1304 (1997).
74. Rahmouni A, Chosidow O, Mathieu D et al. MR imaging in acute infectious cellulitis. Radiology 192(2), 493-496 (1994).
75. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. Am. J. Roentgenol. 170(3), 615-620 (1998).
76. Wang TL, Hung CR. Role of tissue oxygen saturation monitoring in diagnosing necrotizing fasciitis of the lower limbs. Ann. Emerg. Med. 44(3), 222-228 (2004).
77. Barie PS. The laboratory risk indicator for necrotizing fasciitis (LRINEC) score: useful tool or paralysis by analysis? Crit. Care Med. 32(7), 1618-1619 (2004).
78. Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South. Med. J. 90(11), 1065-1068 (1997).
79. Majeski JA. Alexander JW. Early diagnosis, nutritional support, and immediate extensive debridement improve survival in necrotizing fasciitis. Am. J. Surg. 145(6), 784-787 (1983).
80. Voros D, Pissiotis C, Georgantas D et al. Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. Br. J. Surg. 80(9), 1190-1191 (1993).
81. Ward RG. Necrotising fasciitis. Immediate surgical opinion is essential. Br. Med. J. 309(6950), 341 (1994).
82. Burge TS, Watson JD. Necrotising fasciitis. Br. Med. J. 308(6942), 1453-1454 (1994).
83. Miller LG. Fourteen cases with necrotizing fasciitis caused by community-onset MRSA in Los Angeles. 42nd Annual Meeting of IDSA Boston, MA, USA, 27-28 September 2004.
84. Mulla ZD. Treatment options in the management of necrotising fasciitis caused by group A Streptococcus. Expert Opin. Pharmacother. 5(8), 1695-1700 (2004).
85. Coyle EA. Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 23(5), 638-642 (2003).
86. Coyle EA, Cha R, Rybak MJ. Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release. Antimicrob. Agents Chemother. 47(5), 1752-1755 (2003).
87. Mascini EM, Jansze M, Schouls LM et al. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int. J. Antimicrob. Agents 18(4), 395-398 (2001).
88. Shibl AM, Al-Sowaygh IA. Differential inhibition of bacterial growth and hemolysin production by lincosamide antibiotics. J. Bacteriol. 137(2), 1022-1023 (1979).
89. Sriskandan S, McKee A, Hall L et al. Comparative effect of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J. Antimicrob. Chemother. 40(2), 275-277 (1997).
90. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin. Infect. Dis. 20(Suppl. 2), S154-S157 (1995).
91. Kishi K, Hirai K, Hiramatsu K et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1β. Antimicrob. Agents Chemother. 43(3), 616-622 (1999).
92. Murakami J, Kishi K, Hirai K et al. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int. J. Antimicrob. Agents 15(2), 103-109 (2000).
93. Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome-associated exotoxin production. J. Infect. Dis. 149(3), 471 (1994).
94. Stevens DL, Maier KA, Laine BM et al. Comparison of clindamycin, rifampin, tetracycline, metronidazole and penicillin for efficacy in prevention of experimental GAS gangrene due to Clostridium perfringens. J. Infect. Dis. 155(2), 220-228 (1987).
95. Stevens DL, Maier KA, Mitten JE. Eftect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob. Agents Chemother. 31(2), 213-218 (1987).
96. Van Langevelde P, van Dissd JT, Ravensbergen E. Antibiotic-induced release of lipotechoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob. Agents Chemother. 42, 3078 (1998).
97. Hirata N, Hiramatsu K, Kishi K et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob. Agents Chemother. 45(9), 2638-2642 (2001).
98. Nakano T, Hiramatsu K, Kishi K et al. Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages. Antimicrob. Agents Chemother. 47(1), 363-367 (2003).
99. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am. J. Med. 13, 3899 (1952).
100. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J. Infect. Dis. 167, 1401-1405 (1993).
101. Stevens DL, Gibbons AE, Bergstrom R et al. The Eagle effect revisited: efficacy of clidamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23-28 (1988).
102. Demello FJ, Haglin JJ, Hitchcock CR. Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen. Surgery 73, 936 (1973).
103. Kindwall EP. Uses of hyperbaric oxygen therapy in the 1990s. Cleve. Clin. J. Med. 59(5), 517-528 (1992).
104. Nachreiner R, Childers B, Kizzar R et al. Adjunctive hyperbaric oxygen therapy for necrotizing fisciitis: a 10-year experience. Plast. Surg. Forum 18, 334-335 (1995).
105. Cawley MJ, Briggs M, Haith LR Jr et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy 19(9), 1094-1098 (1999).
106. Kaul R, McGeer A, Norrby-Teglund A et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 28(4), 800-807 (1999).
107. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand. J. Infect. Dis. 35(9), 683-689 (2003).
108. Patel R, Rouse MS, Florez MV et al. Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis. J. Infect. Dis. 181(1), 230-234 (2000).
109. Norrby-Teglund A, Kaul R, Low DE et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect. Immun. 64(12), 5395-5398 (1996).
110. Skansen-Saphir U, Andersson J, Bjork L et al. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively downregulated by pooled human IgG. Eur. J. Immunol. 24(4), 916-922 (1994).
111. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T-cells by staphylococcal toxin superantigens. J. Clin. Invest. 91(2), 602-607 (1993).
112. Andersson U, Bjork L, Skansen-Saphir U et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol. Rev. 139, 21-42 (1994).
113. Stevens DL. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin. Infect. Dis. 26(3), 639-641 (1998).
114. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 92(5), 2533-2539 (1993).
115. Norrby-Teglund A, Ihendyane N, Kansal R et al. Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens. Clin. Infect. Dis. 31(5), 1175-1182 (2000).
116. Darenberg J, Soderquist B, Normark BH et al. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin. Infect. Dis. 38(6), 836-842 (2004).
117. Norrby-Teglund A, Basma H, Andersson J et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin. Infect. Dis. 26(3), 631-638 (1998).
118. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med.. 344(10), 699-709 (2001).
119. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, anti-adhesive, and pro-inflammatory attributes. Blood 90(10), 3819-3843 (1997).
120. Purnell D, Hazlett T, Alexander SL. A new weapon against severe sepsis related to necrotizing fasciitis. Dimens. Crit. Care Nurs. 23(1), 18-23 (2004).
121. Hall MA, Stroop SD, Hu MC et al. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun. 72(5), 2507-2512 (2004).
122. Kotloff KL, Corretti M, Palmer K et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: Phase 1 trial. J. Am. Med. Assoc. 292(6), 709-715 (2004).
123. Guzman CA, Talay SR, Molinari G et al. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J. Infect. Dis. 179(4), 901-906 (1999).
124. Dale JB, Chiang EY, Hasty DL et al. Antibodies against a synthetic peptide of SAgA neutralize the cytolytic activity of streptolysin S from group A streptococci. Infect. Immun. 70(4), 2166-2170 (2002).
125. McCormick JK, Tripp TJ, Olmsted SB et al. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J. Immunol. 165(4), 2306-2312 (2000).
126. Roggiani M, Stoehr JA, Olmsted SB et al. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect. Immun. 68(9), 5011-5017 (2000).
127. Hasenbein ME, Warner JE, Lambert KG et al. Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area. J. Clin. Microbiol. 42(4), 1559-1563 (2004).
128. Tarkowski A, Collins LV, Jonsson IM et al. Microbial superantigens as virulence factors and ways to counteract their actions. Scand. J. Infect. Dis. 35(9), 642-646 (2003).
129. Hidalgo-Grass C, Dan-Goor M, Maly A et al. Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections. Lancet 363(9410), 696-703 (2004).
130. Arad G, Hillman D, Levy R et al. Broad spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide. Immunol. Lett. 91(2-3), 141-145 (2004).
131. Arad G, Hillman D, Levy R et al. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock. J. Leukoc. Biol. 69(6), 921-927 (2001).
132. Arad G, Levy R, Hillman D et al. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nature Med. 6(4), 414-421 (2000).
133. Schlievert PM. Will therapeutic peptides be kryptonite for superantigens? Nature Med. 6(4), 378-379 (2000).
134. Cole L, Bellomo R, Journois D et al. High-volume haemofiltration in human septic shock. Intensive Care Med. 27(6), 978-986 (2001).
135. Fenwick P, Ryan C, Sriskandan S et al. Application of a rat model of streptococcal shock to evaluate on-line hemoperfusion and removal of circulating superantigens. Cit. Care Med. 31(1), 171-178 (2003).
136. Ronco C, Inguaggiato P, D'Intini V et al. The role of extracorporeal therapies in sepsis. J. Nephrol. 16(Suppl. 7), S34-S41 (2003).
137. Stegmayr BG. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Ther. Apher. 5(2), 123-127 (2001).
138. Stegmayr BG. The presence of superantigens and complex host responses in severe sepsis may need a broad therapeutic approach. Ther. Apher. 5(2), 111-114 (2001).
139. Herwald H, Collin M, Muller-Esterl W et al. Streptococcal cysteine proteinase releases kinins: a virulence mechanism. J. Exp. Med. 184(2), 665-673 (1996).
140. Herwald H, Cramer H, Morgelin M et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116(3), 367-379 (2004).
141. Herwald H, Morgelin M, Bjorck L. Contact activation by pathogenic bacteria: a virulence mechanism contributing to the pathophysiology of sepsis. Scand. J. Infect. Dis. 35(9), 604-607 (2003).
142. Bjorck L, Akesson P, Bohus M et al. Bacterial growth blocked by a synthetic peptide based on the struction of a human proteinase inhibitor. Nature 337, 385-386 (1989).
143. Wall DB, de Virgilio C, Black S et al. Objective criteria may assist in distinguishing necrotizing fasciitis from non-necrotizing soft tissue infection. Am. J. Surg. 179(1), 17-21 (2000).